SCM
PALI icon

Superstring Capital Management’s Palisade Bio PALI Stock Holding History

Superstring Capital Management’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-367,103
Closed -$863K – 48
2025
Q4 		$863K Buy
+367,103
New +$706K 0.46% 38

Other funds holding PALI

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Superstring Capital Management's PALI Position: Q1 2026 in Review

Superstring Capital Management sold out of Palisade Bio (PALI) in Q1 2026, closing a stake of 367,103 shares — an estimated $863K sold.

Superstring Capital Management first reported a position in PALI in Q4 2025 and held it in 1 quarter. The position peaked at $863K in Q4 2025. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

  • Superstring Capital Management reported no remaining Palisade Bio position as of Q1 2026 after selling out during the quarter.
  • Superstring Capital Management sold 367,103 Palisade Bio shares in Q1 2026, an estimated $863K.
  • Superstring Capital Management first reported a position in Palisade Bio in Q4 2025 and held it in 1 quarter.
  • Superstring Capital Management's Palisade Bio position peaked at $863K in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.